OpenAI acquires Orchestra Bio, a drug development coordination platform

On 20 October 2026 OpenAI announced that it has acquired Orchestra Bio, a platform built to help biopharma teams coordinate the many parts of drug development. Orchestra's team, which OpenAI describes as experienced across biotech, software and AI, and its technology are being combined with Rosalind, OpenAI's AI models and tools for life sciences research. The stated goal is to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

On Orchestra's platform, scientists and program leaders hand the monitoring and tracking of studies and campaigns to AI agents. When a problem in one part of a program affects others, for example a failed manufacturing batch that delays the start of a clinical trial, the agents find the affected activities and timelines, gather the relevant information and compare possible responses. People then decide what to do next.

Within Rosalind, GPT-Rosalind helps scientists reason through questions in biology and chemistry, and Rosalind Workbench links those capabilities with scientific tools and data. OpenAI notes that bringing a new medicine from target discovery to regulatory approval in the United States takes roughly 10 to 15 years on average. The announcement does not state a purchase price or a timeline for new products.